Bernstein lowered the firm’s price target on Alnylam (ALNY) to $447 from $448 and keeps an Outperform rating on the shares. The firm notes Amvuttra beat consensus by 5%. Shares ended the day up only 3%, lower than the mid-single digit Bernstein expected, with bear feedback that the beat relied too much on outside-U.S. guide midpoint still requires large step-up in quarter-over-quarter growth. The firm thinks U.S. numbers look very strong with continued gains vs. competitors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALNY:
- Outside Review Warns Alnylam Pharmaceuticals Stock Carries High Risk of Significant Losses
- Alnylam Earnings Call Highlights TTR-Fueled Breakout
- Alnylam reports Q1 EPS $1.99, consensus $1.47
- Myles Minter Reiterates Buy on Alnylam After Strong Beat, Reaffirmed 2026 Outlook, and Advancing TRITON Phase III Pipeline
- ALNY Earnings Report this Week: Is It a Buy, Ahead of Earnings?